In a report released today, Gary Nachman from BMO Capital reiterated a Buy rating on PolyPid (PYPD – Research Report), with a price target of $27.00. The company’s shares closed last Thursday at $4.58, close to its 52-week low of $3.92.
According to TipRanks.com, Nachman ‘s ranking currently consits of 0 on a 0-5 ranking scale, with an average return of -7.7% and a 41.4% success rate. Nachman covers the Healthcare sector, focusing on stocks such as Bausch Health Companies, Aquestive Therapeutics, and Ionis Pharmaceuticals.
PolyPid has an analyst consensus of Strong Buy, with a price target consensus of $21.00, representing a 358.5% upside. In a report released yesterday, JMP Securities also reiterated a Buy rating on the stock with a $15.00 price target.
See Insiders’ Hot Stocks on TipRanks >>
Based on PolyPid’s latest earnings release for the quarter ending March 31, the company reported a quarterly GAAP net loss of $11.87 million. In comparison, last year the company had a GAAP net loss of $8.69 million.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
PolyPid Ltd was incorporated under the laws of Israel and commenced its operations on February 28, 2008. The Company is a clinical stage specialty pharmaceutical company engaged in research and development of products based on PLEX (Polymer-Lipid Encapsulation MatriX), the Company’s proprietary drug delivery technology. PLEX is capable of encapsulating many types of drugs to enable targeted, localized drug delivery into the body over extended periods of time with pre-determined release rates thus optimizing drug treatment regimens. BonyPid, BonyPid-1000, BonyPid-500, PLEX, and D-PLEX are trademarks of the Company. The Company is subject to extensive regulation by the FDA, under the Federal Food, Drug, and Cosmetic Act, as well as by other federal, state, and local regulatory agencies.
Read More on PYPD:
- Franklin Covey Company (FC) Receives a Buy from Barrington
- Jim Cramer Says Earnings Estimate Cuts Will Form an Investable Bottom; Here Are 3 ‘Strong Buy’ Stocks That Are Already Down 50%
- Zoom Steps Up Its Game as Professionals Get Back to the Salt Mines
- Barrington Sticks to Its Hold Rating for Methode Electronics (MEI)
- H.C. Wainwright Keeps Their Hold Rating on Celyad (CYAD)